BostonGene will analyze the tumors of patients enrolled in NEC or NEC-affiliated clinical trials and NEC will use the data to help improve treatment responses.
A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.
Comprehensive analysis by a team led by Elaine Mardis has given 93 percent of around 150 pediatric cancer patients at least one medically actionable finding.
